Antisense Therapeutics Limited (ATHJF) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Drug Manufacturers - Specialty & Generic उद्योग. कंपनी का मुख्यालय है Toorak, VIC, Australia. वर्तमान CEO हैं James Garner MBA.
ATHJF के पास है IPO तिथि 2009-09-08, पर सूचीबद्ध Other OTC, बाजार पूंजीकरण $19.64M.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
